Tesamorelin vs MK-677
GHRH Analog · GH Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
Tesamorelin
The only GHRH analog with current FDA approval; daily injection for visceral fat reduction in HIV-associated lipodystrophy.
MK-677
An oral GH secretagogue activating the ghrelin receptor in pill form; not FDA-approved, with metabolic trade-offs.
Tesamorelin
110 studies
37 human trials
FDA-Approved
MK-677
134 studies
24 human trials
Not FDA-Approved
What it does
Tesamorelin
Currently the only FDA-approved GHRH analog. Marketed as Egrifta to reduce visceral fat in HIV patients whose antiretroviral medications cause abnormal fat redistribution. A small chemical modification at the front of the peptide protects it from being broken down, which is what gives the FDA-label dose its sustained growth hormone response rather than the minutes-long signal native GHRH would produce.
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
How it works
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that improves stability. It binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release that follows the body's natural rhythm. The downstream GH elevation reduces visceral adipose tissue through increased lipolysis and hepatic fat oxidation.
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
How often
Tesamorelin
FDA labeling for Egrifta specifies daily subcutaneous injection for the HIV-associated lipodystrophy indication. The compound is not FDA-approved for any indication outside HIV-associated visceral fat reduction.
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
How strong
Tesamorelin
FDA-approved with completed Phase III trials demonstrating visceral fat reduction in the HIV-associated lipodystrophy population. The Phase III STARS trial showed significant reduction in trunk fat. GH and IGF-1 elevation documented across multiple studies. The only GHRH analog that achieved and maintained FDA approval through a complete regulatory process.
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
Main tradeoff
Tesamorelin
FDA-approved but only for HIV-associated lipodystrophy, a narrow indication. Off-label use for body composition or anti-aging in non-HIV populations is common in clinical practice but lacks the Phase III data that supports the approved use. The compound is more expensive than non-FDA-approved GHRH analogs (sermorelin, CJC-1295) because it carries the regulatory and manufacturing costs of an FDA-approved pharmaceutical product.
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
Best for
Tesamorelin
- Adults with diagnosed HIV-associated lipodystrophy under physician supervision
- Research comparing FDA-approved versus non-approved GHRH analogs
- Clinical contexts where FDA-approved GH-stimulating therapy is required by protocol
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
How to choose
A good fit for Tesamorelin
- Clinical treatment for HIV-associated lipodystrophy under physician supervision
- Research contexts where FDA-approved status and Phase III data are required
- Research prioritizing GHRH-receptor GH release with minimal metabolic disruption
A good fit for MK-677
- Research on oral GH secretagogue mechanisms and ghrelin-receptor pharmacology
- Research contexts where injection avoidance is the primary constraint
- Research on ghrelin-mediated appetite and metabolic signaling alongside GH elevation
Consider both across time
Tesamorelin and MK-677 raise endogenous growth hormone through different receptor pathways with fundamentally different evidence bases. Tesamorelin is the regulatory gold standard in the GHRH analog class with FDA approval, but only for one narrow indication (HIV-associated visceral fat). MK-677 is the oral convenience option with short-term human trial data but a broader metabolic side effect profile and no FDA approval. The choice often depends on whether regulatory validation, delivery route, or metabolic side effect tolerance matters most for the specific context.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates Pituitary Somatotrophs; Ghrelin Receptor (GHS-R1a) activates Pituitary Somatotrophs
- Pituitary Somatotrophs stimulates Pulsatile GH Release
- Pulsatile GH Release connects to IGF-1 Elevation; Liver IGF-1 Production connects to IGF-1 Elevation
- Pulsatile GH Release drives Visceral Fat Lipolysis
- Visceral Fat Lipolysis connects to Visceral Adipose Reduction
- Ghrelin Receptor (GHS-R1a)
- Pituitary Somatotrophs connects to Growth Hormone Release
- Growth Hormone Release stimulates Liver IGF-1 Production
Tesamorelin activates the GHRH receptor on pituitary somatotrophs with a trans-3-hexenoic acid modification for improved stability.
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form rather than injection.
Research Evidence
Tesamorelin has the stronger regulatory evidence: completed Phase III (STARS trial demonstrating significant trunk fat reduction) and FDA approval for HIV-associated lipodystrophy. MK-677 has more published endpoints across short-term trials: GH/IGF-1 elevation, body composition, bone turnover, and sleep quality over 8 to 24 weeks. The evidence structures are qualitatively different: tesamorelin met the FDA approval bar for one indication; MK-677 accumulated trial data across multiple endpoints without completing the Phase III process.
- 1.
For HIV-associated lipodystrophy under physician supervision, tesamorelin is the FDA-approved option.
- 2.
For oral GH secretagogue research, MK-677 is the only option.
- 3.
For GHRH-mediated GH research with regulatory validation, tesamorelin leads.
- 4.
For cost and oral convenience considerations, MK-677 is more accessible.
Key Limitations
- •No head-to-head trial exists.
- •Tesamorelin's approval is specific to HIV lipodystrophy.
- •MK-677 has never completed Phase III.
- •Long-term safety for off-label body composition use is not characterized for either compound.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Tesamorelin
"Tesamorelin is the only FDA-approved peptide that actually reduces belly fat"
Supported by published data
"It is better than regular GH for fat loss because it does not cause insulin resistance"
Plausible but unproven
"Biohackers are using it off-label for general fat loss"
Anecdotal only
MK-677
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Safety Comparison
Tesamorelin has a well-characterized safety profile from Phase III trials and FDA post-market surveillance. MK-677's safety profile includes metabolic effects (appetite increase, potential glucose and insulin sensitivity changes, water retention) and the elderly hip-fracture CHF signal from the Murphy 2008 study. FDA labeling for tesamorelin includes a carcinogenicity warning. Neither compound's long-term safety for off-label body composition use is well-characterized in non-trial populations.
Tesamorelin
Well-characterized from Phase III trials. Side effects include injection site reactions, joint pain, and peripheral edema.
MK-677
Multiple short-term trials. Appetite increase, potential glucose and insulin sensitivity effects, water retention. Elderly hip-fracture study CHF signal.
What the Research Suggests
Tesamorelin is the regulatory standard among GH-stimulating compounds with FDA approval for one specific indication. MK-677 is the oral convenience alternative with broader short-term trial data but no regulatory milestone.